Holen Sie sich die Stockscreener-App
79.20
8.74%
-7.795
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
J&J Could Be Latest Protagonist In M&A Merry-Go-Round - insights.citeline.com
Is Protagonist Therapeutics Inc. a candidate for recovery playTrade Risk Report & AI Driven Stock Reports - newser.com
How Protagonist Therapeutics Inc. stock reacts to job market data2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy - Benzinga
Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale (NASDAQ:PTGX) - Seeking Alpha
Protagonist Therapeutics Reaches Analyst Target Price - Nasdaq
How Protagonist Therapeutics Inc. stock responds to policy changes2025 Risk Factors & Fast Gain Stock Tips - newser.com
J&J in talks to acquire Protagonist Therapeutics - Yahoo Finance
Protagonist Therapeutics stock price target raised to $112 by BMO Capital - Investing.com Canada
News impact scoring models applied to Protagonist Therapeutics Inc.2025 Year in Review & Low Drawdown Momentum Ideas - newser.com
Protagonist Therapeutics, Inc. $PTGX Stock Position Cut by Inspire Investing LLC - MarketBeat
Using data models to predict Protagonist Therapeutics Inc. stock movementQuarterly Profit Review & Daily Price Action Insights - newser.com
Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make - Seeking Alpha
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Cincinnati Enquirer
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Pensacola News Journal
Protagonist Therapeutics (PTGX) Surges on Johnson & Johnson Acquisition Talks - GuruFocus
Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more - Seeking Alpha
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - sharewise.com
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 9.4%What's Next? - MarketBeat
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials - ts2.tech
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues - simplywall.st
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighHere's What Happened - MarketBeat
Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Newport Daily News
Pharma, Battery, And Biotech Stocks See Sudden Price Jumps - Finimize
Protagonist Therapeutics (PTGX) Surges on Takeover Speculation - GuruFocus
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - WSAU
Protagonist Therapeutics Stock Notable Surge - timothysykes.com
Protagonist Therapeutics’s Recent Commendable Performance - StocksToTrade
Protagonist Therapeutics stock reaches all-time high at 73.34 USD By Investing.com - Investing.com Nigeria
Sudden Surge: PTGX’s Momentous Journey - timothysykes.com
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs - ts2.tech
Protagonist Therapeutics stock reaches all-time high at 73.34 USD - Investing.com
Protagonist Therapeutics Sees Surging Stock Price: What’s Driving This? - StocksToTrade
Why Did Protagonist Therapeutics Stock Soar Today? - MSN
Protagonist Therapeutics (PTGX) Stock Surges Over 34% - GuruFocus
Johnson & Johnson in Acquisition Talks with Protagonist TherapeuticsNews and Statistics - IndexBox
Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more - CNBC
Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ - Bloomberg.com
Protagonist Therapeutics (PTGX) Surges on Potential Johnson & Jo - GuruFocus
Protagonist Therapeutics surges after media reports J&J in talks to buy co - TradingView
J&J reportedly in talks to buy Protagonist (JNJ:NYSE) - Seeking Alpha
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports - Yahoo Finance
Protagonist Therapeutics stock surges after J&J acquisition talks report By Investing.com - Investing.com South Africa
Johnson & Johnson In Talks To Buy Protagonist TherapeuticsWSJ - TradingView
Exclusive | Johnson & Johnson in Talks to Buy Protagonist Therapeutics - The Wall Street Journal
Protagonist Therapeutics' (PTGX) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
What machine learning models say about Protagonist Therapeutics Inc.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
Protagonist Stock Surges on Johnson & Johnson Report - The Wall Street Journal
Predicting Protagonist Therapeutics Inc. trend using moving averages2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
Protagonist Therapeutics (PTGX): Evaluating Valuation After Positive Phase 2b Trial Data and Pipeline Momentum - simplywall.st
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - El Paso Times
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):